Abstract:Shannon S Zhang, 1 Viola W Zhu 1, 2 1 University of California, Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2 Chao Family Comprehensive Cancer Center, Orange, CA, USA Correspondence: Viola W Zhu University of California, Irvine School of Medicine, Department of Medicine, 200 S Manchester Ave, Suite 410, Orange, CA, 92868, USA Tel +1 714-456-8105 Fax +1 714-456-2242 Email The EGFR exon 20 insertion ( EGFR ex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants of EGFR ex20ins mutations have been identified with A767_V769dupASV being the most common variant across multiple surveys. Treatment with currently available EGFR tyrosine kinase inhibitors (TKIs) including osimertinib is generally ineffective. Amivantamab (JNJ-372), a bispecific monoclonal antibody against EGFR and MET, has recently been approved by the US FDA for patients with advanced or metastatic NSCLC harboring EGFR ex20ins mutations after disease progression on platinum-based chemotherapy. Among all the TKIs in clinical development, mobocertinib (TAK-788) has been granted priority review by the FDA for the same indication as amivantamab. Here, we provide a concise review on mobocertinib, with a focus on its chemical structure, preclinical data, and phase 1/2 trial results. Future directions will likely focus on combination approach such as TKI plus chemotherapy in the first-line setting, designing drugs with CNS activity, and exploring disease characteristics of various EGFR ex20ins mutation variants and how they may affect treatment response. Keywords: mobocertinib, TAK-788, NSCLC, EGFR exon 20 insertion, TKI, amivantamab The EGFR exon 20 insertion ( EGFR ex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC), constituting up to 12% of NSCLC cases harboring EGFR mutations. 1 This molecular alteration is characterized by in-frame insertions and/or duplications clustered between codons 762 and 774, resulting in constitutive activation of the EGFR pathway. 2 , 3 More than 50 variants of EGFR ex20ins mutations have been identified with A767_V769dupASV (ASV) being the most common variant across multiple surveys. 1 , 3 Because most EGFR ex20ins mutations do not have diminished adenosine triphosphate (ATP) binding or increased affinity for EGFR tyrosine kinase inhibitors (TKIs), treatment with EGFR TKIs is generally ineffective. 2 Amivantamab (JNJ-372), a bispecific monoclonal antibody against EGFR and MET, has recently been approved by the US FDA for the treatment of advanced or metastatic NSCLC patients with EGFR ex20ins mutations after disease progression on platinum-based chemotherapy. 4 Mobocertinib (TAK-788) has been granted priority review by the FDA for the same indication. Here we provide a concise review on mobocertinib, with a focus on its chemical structure, preclinical data, phase 1/2 trial results, and future development, in anticipation for its FDA approval in the near future. There is significant overlap in terms of conformation between EGFR ex20ins mutations and wild type (WT) EGFR in the ATP binding pocket, rendering osimertinib's lack of selectivity against EGFR ex20ins mutations. The amino acid insertion in the exon 20 located at the C-helix or the P-loop of the EGFR kinase pushes the C-helix into a permanent active conformation, which is distant from the ATP binding site. 2 Mobocertinib was structurally designed to gain selectivity by targeting proteins in the vicinity of the alpha C-helix, a binding site not exploited by osimertinib. More specifically, in a docking model of osimertinib bound to EGFR ex20ins D770_N771insNPG (NPG) mutation, there remained a vacant pocket accessible by substitution of the pyrimidine ring with mobocertinib's isopropyl ester. This structure design allowed mobocertinib to have increased binding affinity for EGFR ex20ins mutations than osimertinib. In addition, mobocertinib is an irreversible EGFR TKI that covalently binds to cysteine 797 in EGFR, similar to afatinib and osimertinib. 3 The chemical structure is shown in Figure 1 . Figure 1 Chemical structure of mobocertinib. In Ba/F3 cells, mobocertinib exhibited inhibitory activity against 14 EGFR mutations with IC 50 ranging from 2.7 to 22.5 nM while IC 50 -Abstract Truncated-

Metabolism and Excretion of [14C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Characterization and Management of Adverse Events Observed with Mobocertinib (TAK-788) Treatment for EGFR Exon 20 Insertion–positive Non–small Cell Lung Cancer

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion (ex20ins)+ Metastatic NSCLC (mnsclc): Additional Results from Platinum-Pretreated Patients (pts) and EXCLAIM Cohort of Phase 1/2 Study.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

Mobocertinib: Mechanism of action, clinical, and translational science

Targeting <i>HER2</i> Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations

Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

FP09.02 Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

An International Real-World Safety and Efficacy Analysis

Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes

Abstract B153: Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies

Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Metabolic Disposition of [14c]‐abivertinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: Role of Glutathione Conjugation